Press release
Investigation announced for Investors in shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) over takeover
An investigation on behalf of investors of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) in connection with the proposed takeover.
Investors who purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and currently hold any of those NASDAQ: ALXN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Alexion Pharmaceuticals, Inc. breached their fiduciary duties owed to NASDAQ: ALXN investors in connection with the proposed acquisition.
Boston, MA based Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. On Dec. 12, 2020, AstraZeneca and Alexion Pharmaceuticals, Inc. have entered into an agreement for AstraZeneca to acquire Alexion. Under the terms of the proposed transaction Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share.
Based on AstraZeneca's reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share.
However, given that at least one analyst has set the high target price for NASDAQ: ALXN shares at $200.00 per share, the investigation concerns whether the offer is unfair to NASDAQ: ALXN stockholders. More specifically, the investigation concerns whether the Alexion Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Alexion Pharmaceuticals, Inc. reported that its annual Total Revenue rose from over $4.13 billion in 2018 to over $4.99 billion in 2019, and that its EBIT rose from $340.4 million in 2018 to over $2.25 billion in 2019.
Those who are current investors in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) over takeover here
News-ID: 2216209 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Alexion
Soliris (Eculizumab) Market Size, Trends, And Forecast to 2033 Alexion
Soliris (Eculizumab) is a monoclonal antibody that inhibits the complement protein C5, a key part of the complement cascade, preventing its cleavage into C5a and C5b. This action effectively blocks the formation of the membrane attack complex (MAC), which is implicated in the destruction of red blood cells and tissue damage in certain autoimmune and inflammatory diseases. It is FDA-approved for rare, life-threatening conditions such as paroxysmal nocturnal hemoglobinuria (PNH),…
Soliris Market Size, Growing Demand to 2033 Alexion
Soliris (eculizumab) is a groundbreaking monoclonal antibody used to treat rare, life-threatening diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). It works by inhibiting the complement system, a part of the immune response that can attack healthy cells when overactivated. Approved by the FDA in 2007, Soliris was one of the most expensive drugs globally, reflecting its role in addressing ultra-rare conditions.…
C5 Complement Inhibitors Market Dynamics Analysis - Alexion, ChemoCentryx
The report titled Global C5 Complement Inhibitors Market offers a robust assessment of the market to understand the scope of the growth potential, revenue growth, product range, and pricing factors besides analyzing the market size, market performance, and market dynamics of the market. This report is professional and a detailed report focusing on primary and secondary drivers, market share, leading segments, and geographical analysis. The report concentrate on the development…
Myasthenia Gravis Treatment Market Forecast 2020-26, Alexion Pharmaceutical, Gri …
The latest study on the Global Myasthenia Gravis Treatment market report represents a deep appraisal of the international industry. The research report on the worldwide Myasthenia Gravis Treatment market 2020-2026 sheds light on qualitative as well as quantitative insights, historical Myasthenia Gravis Treatment industry status and authorized projection related to the Myasthenia Gravis Treatment market size. Each and every segment exhibited in this report are discovered through verifiable research methods…
Mike Page, Alexion Pharmaceuticals invite to SMi's Orphan Drugs & Rare Diseases …
SMi Reports: Mike Page, Executive Director Global Regulatory Affairs Portfolio Products at Alexion Pharmaceuticals invites heads of medical affairs and all who are interested to SMi’s 9th Annual Conference on Orphan Drugs & Rare Diseases.
Mike Page will be co-chairing the conference with Rick Thompson, CEO at Findacure, which will be taking place on 15th and 16th October in London.
This conference will bring together a broad spectrum of experts from…
Global Soliris Market Report 2019 Companies included Alexion and Others
We have recently published 7th edition of market research report on Soliris. For inquiry email us at: sales@marketreportscompany.com
Report includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast till 2026 in terms of volume, revenue, YOY growth rate, and CAGR. The report also provides detailed segmentation on the basis of product type, applications and regional segmentation. The regional segment is…
